Pediatric Cardiology

, Volume 38, Issue 5, pp 974–980 | Cite as

Trends in National Institutes of Health-Funded Congenital Heart Disease Research from 2005 to 2015

  • Kristin M. Burns
  • Victoria L. Pemberton
  • Charlene A. Schramm
  • Gail D. Pearson
  • Jonathan R. Kaltman
Original Article
  • 155 Downloads

Abstract

In an era of ongoing need for research to enable evidence-based care for the expanding population with congenital heart disease (CHD), economic fluctuations have impacted research funding. We characterize trends in NIH-funded CHD research from 2005 to 2015. We searched the NIH RePORTER database from 2005 to 2015 using the terms “congenital heart” and “cardiac morphogenesis”. Projects were characterized by year, institute, mechanism, costs, type and topic, and funding trends were analyzed. From 2005 to 2015, NIH funded 633 CHD research projects with total costs of $991 million. The National Heart, Lung, and Blood Institute funded 83% of CHD projects (528, $857 million). The R01 mechanism was used for 45% of projects (288, $421 million). Projects were 70% basic/early translational research, 27% clinical research, and 3% both. Cardiac developmental biology was the most common topic (52%), followed by technology/therapy development (15%), and diagnosis/management (12%). The total number of CHD projects ranged from 153 to 221 per year (30–58 new projects/year), and costs per year ranged from $58 to $116 million. The number of projects and total costs increased until 2012, but decreased again thereafter. CHD research did not experience as much erosion as overall NIH purchasing power; in constant dollars, CHD research funding levels in 2015 were $12 million higher than those in 2005. The NIH supported a diverse portfolio of CHD projects from 2005 to 2015. Support of CHD research projects trended upward until 2012, but declined thereafter due to fiscal austerity measures.

Keywords

Congenital heart defect Pediatrics Trials Research Funding 

Abbreviations

CHD

Congenital heart disease

NIH

National Institutes of Health

RePORT

Research Portfolio Online Reporting Tools

RePORTER

Research Portfolio Online Reporting Tools Expenditures and Results

SBIR/STTR

Small business projects

NHLBI

National Heart, Lung, and Blood Institute

NICHD

Eunice Kennedy Shriver National Institute of Child Health and Human Development

PHN

Pediatric Heart Network

ARRA

American Recovery and Reinvestment Act

RPG

Research project grants

Notes

Acknowledgements

The authors wish to thank Drs. George Mensah and Bruce Gelb for providing valuable guidance that improved this manuscript.

Funding

No external funding sources were used for this study.

Compliance with Ethical Standards

Conflict of interest

There are no conflicts of interest or relationships with industry to disclose. The views expressed are those of the authors and do not necessarily reflect official National Heart, Lung, and Blood Institute positions.

References

  1. 1.
    Heron M (2011) Deaths: leading causes for 2007. Natl Vital Stat Rep 59(8):1–95PubMedGoogle Scholar
  2. 2.
    Global, regional (2015) and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117–171CrossRefGoogle Scholar
  3. 3.
    Shuler CO, Black GB, Jerrell JM (2013) Population-based treated prevalence of congenital heart disease in a pediatric cohort. Pediatr Cardiol 34(3):606–611CrossRefPubMedGoogle Scholar
  4. 4.
    Mozaffarian D, Benjamin EJ, Go AS et al (2016) Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation 133(4):e38–e360CrossRefPubMedGoogle Scholar
  5. 5.
    Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131(4):e29–e322CrossRefPubMedGoogle Scholar
  6. 6.
    Karamlou T, Diggs BS, Person T, Ungerleider RM, Welke KF (2008) National practice patterns for management of adult congenital heart disease: operation by pediatric heart surgeons decreases in-hospital death. Circulation 118(23):2345–2352CrossRefPubMedGoogle Scholar
  7. 7.
    Dean PN, Hillman DG, McHugh KE, Gutgesell HP (2011) Inpatient costs and charges for surgical treatment of hypoplastic left heart syndrome. Pediatrics 128(5):e1181–e1186CrossRefPubMedGoogle Scholar
  8. 8.
    Connor JA, Gauvreau K, Jenkins KJ (2005) Factors associated with increased resource utilization for congenital heart disease. Pediatrics 116(3):689–695CrossRefPubMedGoogle Scholar
  9. 9.
    Pasquali SK, He X, Jacobs ML et al (2014) Excess costs associated with complications and prolonged length of stay after congenital heart surgery. Ann Thorac Surg 98(5):1660–1666CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Simeone RM, Oster ME, Hobbs CA, Robbins JM, Collins RT, Honein MA (2015) Population-based study of hospital costs for hospitalizations of infants, children, and adults with a congenital heart defect, Arkansas 2006 to 2011. Birth Defects Res A Clin Mol Teratol 103(9):814–820CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gelb BD (2015) History of our understanding of the causes of congenital heart disease. Circ Cardiovasc Genet 8(3):529–536CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Collins FA, Rockey S (2013) One nation in support of biomedical research. https://nexus.od.nih.gov/all/2013/09/24/one-nation-in-support-of-biomedical-research/. Accessed 28 Nov 2016
  13. 13.
    National Institutes of Health (2015) Research Portfolio Online Reporting Tools. http://report.nih.gov/index.aspx. Accessed 23 June 2015
  14. 14.
    National Institues of Health (2016) NIH grants & funding glossary and acronym list. https://grants.nih.gov/grants/glossary.htm. Accessed 30 Dec 2016
  15. 15.
    U.S. Bureau of Labor Statistics (2017) Consumer price index inflation calculator. https://www.bls.gov/data/inflation_calculator.htm. Accessed 4 Jan 2017
  16. 16.
    Gavini N, Hoots WK, Mensah GA, Hanspal M (2015) An analysis of the NIH-supported sickle cell disease research portfolio. Blood Cells Mol Dis 54(2):198–205CrossRefPubMedGoogle Scholar
  17. 17.
    Khoury MJ, Clauser SB, Freedman AN et al (2011) Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomark Prev 20(10):2105–2114CrossRefGoogle Scholar
  18. 18.
    Galis ZS, Thrasher T, Reid DM, Stanley DV, Oh YS (2013) Investing in high blood pressure research: a national institutes of health perspective. Hypertension 61(4):757–761CrossRefPubMedGoogle Scholar
  19. 19.
    Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannids JP, Mandl KD (2012) Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics 130(2):285–292CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hill KD, Chiswell K, Califf RM, Pearson G, Li JS (2014) Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. Am Heart J 167(6):921–929CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2017

Authors and Affiliations

  1. 1.National Heart, Lung, and Blood InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations